JOURNAL of
ONCOLOGICAL
SCIENCES

ORIGINAL RESEARCH ARTICLE

Survival analysis according to lymph nodes dissection and adjuvant therapy types in gastric cancer: A retrospective multicenter cohort study
Received Date : 24 Jul 2019
Accepted Date : 27 Sep 2019
Available Online : 01 Oct 2019
Doi: 10.1016/j.jons.2019.09.004 - Article's Language: EN
J Oncol Sci 5 (2019) 80-84
This is an open access article under the CC BY-NC-ND license
ABSTRACT
Aim: While the main treatment of gastric cancer (GC) is surgery, controversy continues regarding appropriate lymph nodes dissection (LND) types and optimal adjuvant therapy after surgery. Therefore, we aim to analyze the survival outcomes of different treatment sequences in GC. Materials and methods: In total, 234 GC patients who developed recurrence after D1 or D2 LND, R0 gastrectomy were retrospectively investigated. Patients treated with following different treatment sequences were compared for time to recurrence (TTR) and overall survival (OS) of patients with recurrence: D1-LND followed by chemoradiotherapy (CRT) or chemotherapy (CT); D2-LND followed by CRT or CT. RFS and OS estimated by Kaplan-Meier method and long-rank test was used to assess hazard ratio. Results: In the whole group; there were 161 men (68.8%) and mean age was 57.9 (±1.69) years. In 4 arms, 94.8% of patients had positive lymph nodes, 42.7% of patients had pT4 stage tumor, and intestinal-type GC was present in 95 patients (40.6%). The median TTR were 14.0 (11.5e16.5), 7.0 (5.8e8.2), 13.0 (10.5 e15.5), and 13.0 (10.8e15.2) months, for D1-LND þ CRT; D1-LND þ CT; D2-LND þ CRT; and D2-LND þ CT groups, respectively (HR; 95%CI:2086; 1133e3,839, P ¼ 0,018 for D1-LND þ CT group after adjusted for pN stage, PNI, and LVI). The median OS of the patients with recurrence was 29.0 months (26.8e31.2). While higher pT and pN stage, PNI and LVI positivity, undifferentiated and diffuse þ mixed histological types presented with worse overall survival, treatment choices were not effect on OS. Conclusion: RT is not necessary after D2-LND but it is still a major part of adjuvant treatment after D1- LND. D2-LND may not be require to cure GC when appropriate adjuvant treatment is given after D1-LND.
KAYNAKLAR
  1. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725e730. https://doi.org/10.1056/ NEJMoa010187. [Crossref]  [PubMed] 
  2. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30: 2327e2333. https://doi.org/10.1200/JCO.2011.36.7136. [Crossref]  [PubMed]  [PMC] 
  3. Bang YJ, Kim YW, Yang HK, et al. CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315e321. https://doi.org/10.1016/S0140-6736(11)61873-4. [Crossref] 
  4. Park SH, Sohn TS, Lee J, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33: 3130e3136. https://doi.org/10.1200/JCO.2014.58.3930. [Crossref]  [PubMed] 
  5. Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268e273. https://doi.org/10.1200/JCO.2011.39.1953. [Crossref]  [PubMed] 
  6. Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22:2069e2077. https://doi.org/ 10.1200/JCO.2004.08.026. [Crossref]  [PubMed] 
  7. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439e449. https://doi.org/ 10.1016/S1470-2045(10)70070-X. [Crossref] 
  8. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Canc. 1999;79:1522e1530. https:// doi.org/10.1038/sj.bjc.6690243. [Crossref]  [PubMed]  [PMC] 
  9. Enzinger PC, Benedetti JK, Meyerhardt JA, et al. Impact of hospital volume on recurrence and survival after surgery for gastric cancer. Ann Surg. 2007;245: 426e434. https://doi.org/10.1097/01.sla.0000245469.35088.42. [Crossref]  [PubMed]  [PMC] 
  10. Degiuli M, Sasako M, Ponti A, Italian Gastric Cancer Study Group. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg. 2010;97:643e649. https:// doi.org/10.1002/bjs.6936. [Crossref]  [PubMed] 
  11. Kim Y, Park SH, Kim KM, et al. The influence of metastatic lymph node ratio on the treatment outcomes in the adjuvant chemoradiotherapy in stomach tumors (ARTIST) trial: a phase III trial. J Gastric Canc. 2016;16:105e110. https:// doi.org/10.5230/jgc.2016.16.2.105. [Crossref]  [PubMed]  [PMC] 
  12. Dikken JL, Jansen EP, Cats A, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010;28:2430e2436. https://doi.org/10.1200/JCO.2009.26.9654. [Crossref]  [PubMed]